Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma

Figure 6

Cabozantinib alters the phenotype of renal cancer cells. 786-O and ACHN cells were exposed to 2.5 μg/ml cabozantinib or vehicle for 24 h then analyzed by flow cytometry for surface expression of EGFR and PD-L1. (a) Representative figures from each group are shown, . (b) The corresponding quantitative analysis results of EGFR and PD-L1 expression in 786-O and ACHN cells shown in (a). ; .

(a)

(b)